

4/14/2020; Page 1

	Suggested Formula	Sterile – HD and No	n-HD	FIN		
SPECIAL PREPARATORY CONSIDERATIONS						
	Special Instruction:		This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling- healthcare.			
			This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP 797</i> and <i>USP 800</i> , when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.			
			All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.			
			Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.			
			All required personal protective equipment (sterile and hazardous if as but not limited to, gowns, aprons, sleeves, gloves both inner and shoe covers, hairnet, head cap, beard cover, eyewear, appropriate fa and face shield, etc., where applicable must be worn at all times. In personnel cleansing must be done before entering the buffer or clean	outer if ce masl additio	applicable, k, respirator	
			If applicable, follow all required procedures for hazardous drug han not limited to procurement, transport, storage, preparation, dispensit clean up (spills) & disposal.			
			Filter integrity must be validated by performing a filter stress test. If demonstrates that the filter might be defective, the solution must be remade.			
			If you are a registered 503B facility, please refer to all relevant guid including but not limited to the Code of Federal Regulations (CFR), Industry (GFIs) and Compliance Policy Guides (CPGs).			
			This procedure requires the use of very small quantities of ingredier and preparation techniques must be verified before dispensing the fi			

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.